

1 **Heterogeneity in lung macrophage control of *Mycobacterium tuberculosis* is determined**  
2 **by T cells**

3

4

5 **Short title:** T cell containment of Mtb growth

6 Rocky Lai, Travis Williams, Tasfia Rakib, Jinhee Lee, and Samuel M. Behar\*

7

8 Department of Microbiology and Physiological Systems, University of Massachusetts Medical  
9 School, Worcester, Massachusetts, USA.

10

11

12 \*Correspondence:

13 Samuel M. Behar

14 E-mail address: [samuel.behar@umassmed.edu](mailto:samuel.behar@umassmed.edu)

15 **Abstract**

16 Following *Mycobacterium tuberculosis* infection, alveolar macrophages are initially infected but  
17 ineffectively restrict bacterial replication. The distribution of *M. tuberculosis* among different cell  
18 types in the lung changes with the onset of T cell immunity when the dominant infected cellular  
19 niche shifts from alveolar to monocyte-derived macrophages (MDM). We hypothesize that  
20 changes in bacterial distribution among different cell types is driven by differences in T cell  
21 recognition of infected cells and their subsequent activation of antimicrobial effector mechanisms.  
22 We show that CD4 and CD8 T cells efficiently eliminate *M. tuberculosis* infection in alveolar  
23 macrophages, but they have less impact on suppressing infection in MDM, which may be a  
24 bacterial niche. Importantly, CD4 T cell responses enhance MDM recruitment to the lung. Thus,  
25 the outcome of infection depends on the interaction between the T cell subset and the infected  
26 cell; both contribute to the resolution and persistence of the infection.

27

## 28 Introduction

29 *Mycobacterium tuberculosis* causes the chronic lung infection tuberculosis (TB). Following  
30 inhalation of *M. tuberculosis*, alveolar macrophages are initially infected, setting in motion a series  
31 of events that result in the recruitment of numerous cell types to the lung, including both innate  
32 (e.g., neutrophils and macrophages) and adaptive (e.g., B and T cells) immune cells <sup>1, 2, 3</sup>. These  
33 cells cooperate to form granulomas, the characteristic pathological lesion of TB. The fate of  
34 granulomas is varied. Some undergo fibrosis and/or calcification. In others, progressive bacterial  
35 replication leads to dissemination, necrosis, and cavitation. While most people develop immunity  
36 and avoid symptomatic disease, 10% develop clinical TB at some point during their lives.  
37 Impairment of cell mediated immunity greatly increases the risk of developing active TB, and  
38 genetic, environmental, and microbial factors play a role. Understanding how *M. tuberculosis* is  
39 contained is an important question as a major clinical goal is to develop vaccines that prevent  
40 susceptible people from developing disease. A better understanding of the mechanisms that lead  
41 to containment of infection and why they fail in susceptible individuals is needed.

42 Tremendous heterogeneity exists among cells in the myeloid lineage. Monocytes,  
43 macrophages, dendritic cells (DC), and polymorphonuclear cells (PMNs) (hereafter referred  
44 collectively to as “myeloid cells”) both reside in and are recruited to the lung parenchyma during  
45 *M. tuberculosis* infection. Heterogeneity is based on cell ontology but is also shaped by  
46 homeostatic signals specific for the tissue niches where the cells reside (e.g., alveolar  
47 macrophages), and by episodic inflammatory signals that lead to cell recruitment, activation, and  
48 differentiation. After inhalation of aerosols containing *M. tuberculosis*, alveolar macrophages (AM)  
49 are the first cell type in the lung infected <sup>1</sup>. Subsequently, AM in the alveoli traffic into the  
50 parenchyma and trigger innate inflammatory responses. Monocytes and neutrophils are recruited  
51 to the lung. Monocytes differentiate into macrophages and dendritic cells <sup>4, 5</sup>, which *M.*  
52 *tuberculosis* infects <sup>1, 6, 7, 8, 9</sup>. New experimental approaches show that pre-existing heterogeneity  
53 among human macrophages affect *M. tuberculosis* growth <sup>10</sup>. Importantly, macrophages differ in

54 their intrinsic control of *M. tuberculosis* in vivo, which may be triggered by cell-specific responses  
55 <sup>11, 12, 13</sup>. In particular, AM have a metabolic environment that is conducive to bacillary growth by  
56 serving as a source of iron and fatty acids, while glycolytically-biased monocyte-derived  
57 macrophages (MDM) are more restrictive <sup>11, 12, 14</sup>. While AM are the initial cell type infected after  
58 aerosol *M. tuberculosis* infection <sup>1, 12</sup>, after infection is established, the number of infected CD11c<sup>+</sup>  
59 monocyte-derived cells (hereafter, MDM) outnumbers infected AM <sup>1, 9</sup>. While intrinsic features of  
60 infected myeloid cells in the lung may affect their propensity to sustain or restrict *M. tuberculosis*  
61 growth early after infection, we hypothesize that once adaptive immunity is initiated and recruited  
62 to the lungs, T cell immunity will modify the capacity of myeloid cells to restrict *M. tuberculosis*  
63 replication.

64 In animal models, *M. tuberculosis* is controlled within weeks after infection and bacterial  
65 exponential growth is replaced by a plateau phase. The timing of this transition is coincident with  
66 the development of T cell immunity. The use of MHCII<sup>+/+</sup>/MHCII<sup>-/-</sup> mixed bone-marrow chimeric  
67 mice provides direct evidence that cognate interactions between CD4 T cells and infected cells is  
68 important for containment of infection in vivo, although Mtb was not eliminated from MHCII<sup>+</sup> lung  
69 macrophages <sup>15</sup>. Infected CD11c<sup>+</sup> MDM are highly activated, express NOS2, and upregulate  
70 CD14, CD38 and ABCA1, to a greater degree than their uninfected counterparts, providing  
71 additional evidence that infected cells interact with T cells <sup>9</sup>. Yet, it is paradoxical that MDM should  
72 be a dominant reservoir of *M. tuberculosis* and show evidence of being activated by T cells. These  
73 data suggest that T cell control of Mtb-infected macrophages is suboptimal and raises the  
74 possibility of a cellular niche that supports continued bacillary persistence.

75 Not all *M. tuberculosis*-specific T cells efficiently recognize *M. tuberculosis*-infected  
76 macrophages, depending on the antigen <sup>16, 17</sup> and the number of bacilli per macrophage <sup>18, 19, 20</sup>,  
77 <sup>21</sup>. It is unknown whether the interaction of CD4 and CD8 T cells with *M. tuberculosis*-infected  
78 cells varies depending on the type of infected cell. We hypothesize that some *M. tuberculosis*  
79 bacilli occupies a protected cellular niche. We reasoned that for cell types in which *M. tuberculosis*

80 could be eliminated or its growth restricted by T cells, T cell depletion would lead to an increase  
81 in infected cells. In contrast, for cell types in which *M. tuberculosis* persists, even in the face of T  
82 cell pressure, T cell depletion should have minimal effect. We report that CD4 and CD8 T cells  
83 cooperate to restrict *M. tuberculosis* infection in several types of infected cells. *M. tuberculosis*-  
84 infection in AM is efficiently controlled by T cells, particularly by CD4 T cells. In contrast, both CD4  
85 and CD8 T cells are required to restrict *M. tuberculosis* replication in MDM. Interestingly, T cell  
86 depletion had the least effect on MDM compared to other cell types. This hierarchy is the reverse  
87 of the intrinsic capacity of AM and MDM to control bacterial replication early after infection. Thus,  
88 depending on the cell type, the influence of T cells on *M. tuberculosis* containment varies. We  
89 propose that although T cells interact with *M. tuberculosis*-infected MDM, they have a limited ability  
90 to restrict infection in these cells. Although MDM are better than AM in their intrinsic capacity to  
91 restrict intracellular *M. tuberculosis*, once T cell immunity is initiated, AM largely inhibit *M.*  
92 *tuberculosis* growth while T cells contribute only modestly to the ability of MDM to limit intracellular  
93 infection.

94 **Results**

95 **CD4 and CD8 T cells synergize to restrict *M. tuberculosis* growth in the lung.**

96 To determine how T cells exert pressure on different types of *M. tuberculosis*-infected  
97 macrophages, we combined low dose aerosol infection with Rv.YFP<sup>9</sup> and antibody-mediated  
98 depletion of T cells. The in vivo infection was allowed to progress for three weeks, during which  
99 time T cell immunity to *M. tuberculosis* is initiated and recruited to the lung<sup>2,3</sup>. Then, groups of  
100 mice were treated with a control antibody, antibody to CD4, to CD8, or a combination of anti-CD4  
101 and anti-CD8 for two weeks. The mice were analyzed 5 weeks post infection (wpi) (Fig.1a). Both  
102 CD4 and CD8 T cells were eliminated from the lungs of *M. tuberculosis* infected mice, although  
103 CD8 depletion was slightly less efficient (Fig.1b). Neither CD4 nor CD8 T cell depletion led to a  
104 statistically significant increase in lung CFU (Fig.1c). In contrast, the combined depletion of CD4  
105 and CD8 T cells led to an increase in lung CFU (Fig.1c). These data show that early after infection,  
106 both CD4 and CD8 T cells make a synergistic contribution to controlling *M. tuberculosis* replication  
107 in vivo.

108

109 **Monocyte-derived macrophages are the dominant cellular niche for *M. tuberculosis*.**

110 Advances in multiparametric flow cytometry have improved our ability to characterize  
111 myeloid cells in the lung. We adapted our myeloid flow panel for spectral flow cytometry and  
112 measured the distribution of *M. tuberculosis* among different myeloid cell types in the lung, 3- and  
113 5-weeks post-infection. Some important technical features of the panel and its analysis are  
114 described in the *Methods*. Myeloid cells were defined as live CD45<sup>+</sup> cells after lymphoid cells were  
115 excluded based on the CD19, Thy1.2, and NK1.1 lineage markers. Neutrophils and eosinophils  
116 were identified by their expression of Ly6G and SiglecF, respectively (Figure 2a). CD64 and Mertk  
117 distinguished macrophages from non-macrophages (i.e., monocytes and DC).

118 Alveolar macrophages (AM) were discriminated from other lung macrophages by their  
119 high levels of SiglecF and CD11c. CD11b expression divided AM into two subsets. Non-AM

120 macrophages have been called recruited macrophages (RM), interstitial macrophages (IM) and  
121 CD11c<sup>Hi</sup> monocyte-derived cells (MDC) <sup>5, 9, 11, 12</sup>. We previously referred to these cells as CD11c<sup>Hi</sup>;  
122 however, in recognition of heterogeneity in their CD11c expression, we have dropped the CD11c  
123 moniker. As these monocyte-derived cells are distinct from resident macrophages (e.g., AM), we  
124 refer to them as monocyte-derived macrophages (MDM). MDM were divided into three subsets  
125 based on their SiglecF and CD11c expression. The SiglecF<sup>int</sup>CD11c<sup>+</sup> (MDM1) were the most  
126 variable between experiments and could be immature AM <sup>22, 23, 24</sup>. SiglecF<sup>-</sup>CD11c<sup>+</sup> (MDM2) were  
127 the most abundant of the three and were most like what we previously referred to as CD11c<sup>Hi</sup>  
128 MDC (Figure 2a) <sup>9</sup>. In additions, SiglecF<sup>-</sup>CD11c<sup>-</sup> (MDM3) may be nerve associated macrophages  
129 that have been recently described in the lung <sup>25</sup>. Finally, we subdivided monocytes and DC (M/DC)  
130 based on CD11c and Ly6C expression (M/DC1-4). The most abundant of these were M/DC1  
131 (Ly6c<sup>-</sup>CD11c<sup>VAR</sup>) and M/DC3 (Ly6c<sup>+</sup>CD11c<sup>-</sup>). The former was likely a mixed DC population, and  
132 the latter were probably classical monocytes.

133         Between three and five weeks after infection, the total number of macrophages and  
134 monocyte/DCs in the lung significantly increased (Figure S1a). During this interval, the number of  
135 *M. tuberculosis*-infected macrophages increased 5.4-fold, while the number of infected  
136 eosinophils, neutrophils, and monocyte/DCs remained the same. This led to macrophages  
137 becoming the dominant infected cell type (Figure S1b, S1c). With the greater granularity afforded  
138 by spectral flow cytometry, we defined what was driving these changes in 11 predefined cell  
139 subsets (Figure 2a). Between three and five weeks after infection, SiglecF<sup>-</sup>CD11c<sup>+</sup> non-AM  
140 macrophages (i.e., MDM2) underwent a 14-fold increase in cell number such that they accounted  
141 for ~14% of the lung myeloid cells (Figure 2b). M/DC1 cells (Ly6c<sup>-</sup>CD11c<sup>+</sup>), also increased in  
142 number (Figure 2b). Thus, the dominant myeloid cell types in the lung changed from  
143 predominantly neutrophils and monocytes (M/DC3) to macrophages (MDM2) and DC (M/DC1).  
144 This was accompanied by a dramatic shift in the type of cells infected by *M. tuberculosis* (Figure  
145 2c). The number of *M. tuberculosis*-infected non-alveolar macrophages (MDM1, -2, -3) all

146 increased by more than 10-fold. In absolute numbers, MDM2 increased the most and came to  
147 account for 45% of infected cells (Figure 2c). To confirm that these results were not due to  
148 differences in YFP expression between the different macrophage populations, we determined the  
149 intracellular CFU within AM and MDM from the lungs of infected B6 mice. Consistent with our  
150 flow cytometric analysis (Figure 2a, c), MDM had 10-fold more *M. tuberculosis* CFU than AM  
151 (Figure 2d). The significant increase in *M. tuberculosis*-infected macrophage number occurred  
152 despite the onset of T cell immunity during this phase of infection<sup>26, 27</sup>. We hypothesized that  
153 MDM could represent a cellular niche against which T cell immunity inefficiently controlled *M.*  
154 *tuberculosis* replication.

155

### 156 **The effectiveness of T cell immunity depends on the type of infected cell.**

157 We predicted that a cellular niche that was shielded from T cell immunity would be largely  
158 unaffected by T cell depletion, compared to cell types that require T cell signals to restrict  
159 intracellular *M. tuberculosis* replication. As described above, three weeks after infection, once  
160 effector T cells were recruited to the lung, groups of mice were treated with mAb to CD4, CD8 or  
161 both CD4 and CD8 for two weeks. Then, the frequency of *M. tuberculosis*-infected cells was  
162 determined for 11 myeloid cell types by flow cytometry (Figure 1a, 2a).

163 T cell depletion led to a statistically significant increase in the percentage of infected  
164 neutrophils, AM1, MDM1, and MDM2 (Figure 3a, b). Only combined CD4 and CD8 depletion led  
165 to an increased frequency of *M. tuberculosis*-infected neutrophils, suggesting that CD4 and CD8  
166 T cells are redundant in their ability to control infection in these cells (Figure 3b). In contrast, CD4  
167 depletion alone led to a significantly increased frequency of infected AM1, MDM1, and MDM2  
168 (Figure 3a, b). Although CD8 depletion alone had no effect, CD4 and CD8 double depletion  
169 significantly increased the frequency of infected AM1, MDM1, and MDM2 compared to CD4  
170 depletion alone (Figure 3a, b). Importantly, these data indicate CD4 and CD8 T cells act  
171 synergistically to control *M. tuberculosis* infection in macrophages in vivo. Only depletion of CD4



172 and CD8 T cells led to an increase in the number of bacilli per cell in AM1, AM2, and MDM1,  
173 based on the median fluorescence intensity of Rv.YFP (Figure 3c). Interestingly, the Rv.YFP  
174 signal of MDM2, the most abundant infected cell type, was unaffected by T cell depletion (Figure  
175 3c).

176 We next analyzed how T cell pressure affected the frequency of infected cells among all  
177 myeloid cells, since the abundance of each cell type varies. In control (undepleted) mice, MDM2  
178 made the largest contribution (Figure 3d). CD4 T cell significantly augmented the fraction of  
179 infected neutrophils and AM1 among myeloid cells (Figure 3b, 3d). In contrast, CD4 T cell  
180 depletion did not alter the contribution of infected MDM2. While CD8 depletion alone had no effect,  
181 combined anti-CD4 and anti-CD8 mAb treatment significantly increased the frequency of infected  
182 neutrophils and M/DC2, compared to anti-CD4 or CD8 mAb treatment alone. Combined CD4 and  
183 CD8 depletion also increased the fraction of infected MDM1 and MDM2. However, the  
184 contribution of MDM2 to *M. tuberculosis*-infected myeloid cells after CD4+CD8 depletion  
185 increased 1.4-fold (compared to undepleted mice). This change was small compared to the  
186 increased proportion of infected neutrophils or AM1 (9.5- and 5.8-fold, respectively). Thus, even  
187 though MDM are highly activated, their high rate of infection and dominant niche for *M.*  
188 *tuberculosis* raise the possibility that they are inefficiently recognized by T cells<sup>16, 18, 28</sup>.  
189 Conversely, the emergence of other cell populations as an important niche for *M. tuberculosis*  
190 after T cell depletion shows that T cell immunity effectively controls *M. tuberculosis* infection in  
191 other myeloid cell types.

192

### 193 **CD4 T cells maintain high levels of NOS2 expression by macrophages.**

194 Nitric oxide synthase 2 (NOS2) is induced by IFN $\gamma$  in macrophages and its expression is  
195 essential for survival of mice after *M. tuberculosis* infection. NOS2 converts L-arginine into nitric  
196 oxide (NO), which is toxic to *M. tuberculosis*; however, its role in vivo is more complicated as is  
197 its relevance to human TB<sup>29</sup>. NOS2 is expressed by *M. tuberculosis*-infected macrophages in the

198 lung lesions of B6 mice, both by AM and MDM<sup>9, 12, 30</sup>. We measured NOS2 expression by myeloid  
199 cells in the lung following *M. tuberculosis* infection and T cell depletion as described above. At  
200 baseline (i.e., undepleted), 25-42% of MDM1 and MDM2 expressed NOS2 (Figure 4a). Other cell  
201 types such as AM1, MDM3, and M/DC2 also produced significant amounts of NOS2. The NOS2  
202 expression by these different cell types correlated with their degree of infection (Figure 4b,  
203  $r=0.98$ ). In general, more cells in each population expressed NOS2 than were infected. This led  
204 us to determine how many *M. tuberculosis*-infected cells expressed NOS2 (Figure 4c). There  
205 were too few eosinophils and AM2 to generate reliable data. However, for the other subsets, there  
206 was a hierarchy of NOS2 producing cells. Nearly 100% of the *M. tuberculosis*-infected MDM  
207 subsets expressed NOS2. In contrast, ~70% of AM1, 50-60% of M/DC except for M/DC3  
208 produced NOS2. We did not detect intracellular NOS2 in neutrophils (Figure 4c).

209 We next looked at the effect of T cells on the expression of NOS2 in *M. tuberculosis*-  
210 infected cells by segregating the frequency of NOS2<sup>+</sup> vs. NOS2<sup>-</sup> infected cells. After CD4  
211 depletion, slightly more than half of the *M. tuberculosis*-infected cells failed to express NOS2.  
212 CD4 depletion led to an increase in *M. tuberculosis*-infected neutrophils and AM1, and most  
213 infected cells failed to express NOS2 (Figure 4d). Consistent with our previous results, CD8  
214 depletion did not affect the frequency of *M. tuberculosis*-infected cells nor their expression of  
215 NOS2, although it modestly increased the number of infected neutrophils. The ratio of NOS2<sup>+</sup> vs.  
216 NOS2<sup>-</sup> infected cells was decreased after CD4 and CD4+CD8 depletion in all myeloid populations  
217 (Figure 4d, e). Remarkably, although ~50% of the *M. tuberculosis*-infected MDM2 no longer  
218 expressed NOS2 after CD4 or CD4/CD8 depletion, the frequency of infected cells only increased  
219 incrementally (Figure 4d). Interestingly, the ratio of NOS2<sup>+</sup>/NOS2<sup>-</sup> infected cells was increased in  
220 AMs after CD8 depletion but not in MDM (Figure 4d, e). Although NOS2 continues to be  
221 expressed in myeloid cells even in the absence of T cells, these data indicate that CD4 T cells  
222 are crucial for maintaining high levels of NOS2 expression in infected macrophages.

223

224 **Aminoguanidine treatment does not affect control of *M. tuberculosis* infection.**

225 NOS2 is essential for resistance to *M. tuberculosis* infection in B6 mice and mice that lack  
226 the NOS2 gene succumb to infection 4-5 wpi<sup>31</sup>. NO has been suggested to be more important in  
227 regulating inflammation than in direct killing of *M. tuberculosis*<sup>32,33</sup>. We tested whether inhibition  
228 of NOS2 in vivo, through administration of aminoguanidine (AG), would exacerbate *M.*  
229 *tuberculosis* infection as observed with CD4 T cell depletion. To verify that AG treatment was  
230 successful, NO was measured in lung homogenate using the Griess reaction. AG appeared to  
231 have successfully inhibited the production of NO by NOS2 (data not shown). We observed an  
232 increase in the number of viable bacilli in the lungs but not the spleens of mice treated with AG  
233 for two weeks (Figure 5a, 5b). The total number of neutrophils and M/DC3 but not any of the other  
234 myeloid populations were significantly increased after treatment (Figure 5c). The frequency of  
235 infected neutrophils was increased after AG treatment, consistent with the exacerbation of TB  
236 disease as previous described<sup>33</sup>. However, AG treatment did not alter the proportion of infected  
237 cells among the other myeloid subsets (Figure 5d). Thus, it appears that this early stage of *M.*  
238 *tuberculosis* infection after T cell recruitment to the lung, NO has little or no role in the control of  
239 *M. tuberculosis* within macrophage subsets.

240

241 **CD4 T cells drive the recruitment of MDM to the site of infection.**

242 Our data suggests that AM depend on CD4 T cells to augment their intrinsic capacity to  
243 control *M. tuberculosis* (Figure 3a). In contrast, MDMs are less sensitive to the loss of T cell  
244 pressure. T cells secrete numerous chemokines including CCL2, CCL3, and CCL4, which direct  
245 cellular recruitment to the site of infection. As such, we postulated that CD4 T cells recruitment of  
246 myeloid cells to the lung could augment containment of *M. tuberculosis* infection. could recruit  
247 MDM to the lung. To determine whether T cells were important in the recruitment of myeloid cells,  
248 C57BL/6 and RAG<sup>-/-</sup> mice, the latter being devoid of B and T cells, were infected with *M.*  
249 *tuberculosis*. At 3 weeks post infection, CD4 T cells from infected C57BL/6 mouse were

250 transferred via the intravenous route to the RAG<sup>-/-</sup> mice (Figure 6a). As expected, transfer CD4  
251 T cells were sufficient to protect help contain *M. tuberculosis* (Figure 6b). *M. tuberculosis* infection  
252 of RAG<sup>-/-</sup> mice led to an increase in many of the different myeloid cell types in the lung (Figure  
253 6c). Transfer of immune polyclonal CD4 T cells led to a large significant increase in the number  
254 of MDM in the lung (Figure 6c). Immune polyclonal CD4 T cells reduced the fraction of *M.*  
255 *tuberculosis* infected cells (Figure 6d, left) and decreased the intracellular bacillary load, based  
256 on YFP MFI (Figure 6d, right), for most of the myeloid cell types in the lung. Given these effects  
257 of CD4 T cells, one would expect that the total number of *M. tuberculosis* infected cells should  
258 decrease. Although one sees dramatic reductions in the number of infected AM and neutrophils,  
259 the number of infected MDM and other cells did not significantly change (Figure 6e, left). In fact,  
260 because of these changes, CD4 T cells induce a shift in the dominant infected cell type from  
261 neutrophils to MDM (Figure 6e, right).

262

## 263 Discussion

264 The interaction between T cells and infected phagocytes determines the course of *M.*  
265 *tuberculosis* infection. While T cell immunity is required to contain infection, it is not sufficient to  
266 sterilize mice or the approximately 10% of people that develop active tuberculosis. In the murine  
267 TB literature, infection of pulmonary DC has been reported, but using better lineage markers,  
268 multiparametric flow cytometry, and single cell RNASeq, it now appears that CD11c<sup>+</sup>  
269 macrophages are the dominant infected macrophage population in the lung<sup>9, 11, 12</sup>. Given the  
270 inherent diversity of cell types, activation states, and degree of infection of cells in the lung, we  
271 asked whether the impact of T cell immunity is equally distributed among different myeloid cell  
272 types. We hypothesized that there could exist cellular niches in which *M. tuberculosis* is able to  
273 persist because T cells are unable to recognize certain infected cells. Here we report that T cell  
274 control of intracellular infection depends on the type of infected cell. *M. tuberculosis*-infection of  
275 AM is efficiently limited by T cells. In contrast, T cells have only a modest impact on controlling  
276 *M. tuberculosis*-infection among MDM.

277 Using a newly designed flow antibody panel that takes advantage of spectral flow  
278 cytometers, we validated our previous results and those of other labs. Three weeks after low dose  
279 aerosol *M. tuberculosis* infection, most bacilli are found within three cell populations: neutrophils,  
280 macrophages, and monocyte/DCs. By five weeks, relatively few bacteria reside in DC or  
281 monocytes; instead, most *M. tuberculosis* is within macrophages. The macrophages are of two  
282 types: AM and MDM. With additional markers, the macrophages can be subdivided into 5  
283 populations. A priori, these different macrophage populations could reflect different ontogeny or  
284 activation states. For example, significantly more CD11b<sup>+</sup> AM were infected than CD11b<sup>-</sup> AM. As  
285 CD11b is upregulated upon AM activation<sup>9, 11, 12</sup>, we speculate that uninfected CD11b<sup>-</sup> AM could  
286 occupy uninfected regions of the lung. Similarly, we find that the expression of SiglecF and CD11c  
287 among the MDM defined three distinct populations and responded differently to *M. tuberculosis*  
288 infection.

289 CD8 depletion had little or no effect on early *M. tuberculosis* recrudescence in the lung.  
290 Similarly, CD4 depletion led to a statistically significant increase in only one of three experiments.  
291 In contrast, dual depletion led to a dramatic increase in *M. tuberculosis* burden in the lung. The  
292 increase in lung and spleen CFU tracked with the distribution of Rv.YFP in infected cells. An exact  
293 correlation between CFU and YFP<sup>+</sup> should not be expected as flow cytometric analysis cannot  
294 assess extracellular Mtb, differentiate between live and dead bacilli, and only poorly assess the  
295 number of bacilli/cell. CD4 depletion increased the frequency of YFP<sup>+</sup> neutrophils and  
296 macrophages, and the increase of *M. tuberculosis*-infected cells was even greater after dual CD4  
297 and CD8 depletion. The greater perturbation in the distribution of *M. tuberculosis* among myeloid  
298 cells following CD4 but not CD8 depletion suggests that CD4 and CD8 T cell effectors are only  
299 partially redundant<sup>16, 18</sup>. Alternatively, depletion of CD4 T cells might not be efficiently  
300 compensated by CD8 T cells because CD4 T cell help is required to maintain CD8 T cell  
301 antibacterial effector function<sup>34</sup>. The large changes in the frequency of infected cells that occurred  
302 when both CD4 and CD8 T cells were depleted indicates that CD4 and CD8 T cells have a  
303 synergistic role in mediating control of *M. tuberculosis* infection in both AM and MDM subsets.

304 In addition to the synergistic role of CD4 and CD8 T cells in mediating control of *M.*  
305 *tuberculosis* infection, our data also points to differential requirements for these T cell subsets in  
306 helping AM and MDM to contain *M. tuberculosis*. While CD8 T cells appear to have minimal impact  
307 on the ability of AM to control intracellular *M. tuberculosis*, CD8 T cells are important in the ability  
308 of MDM to restrict *M. tuberculosis* growth. We and others have demonstrated that CD8 T cells  
309 are more efficient at recognizing cells with high bacterial burden<sup>20, 21</sup>, and the difference in  
310 intracellular burden between AM and MDM could explain why the two populations react differently  
311 to the loss of CD8 T cell pressure.

312 NOS2 is essential for host resistance to *M. tuberculosis* infection in B6 mice, and mice  
313 that lack the NOS2 gene succumb to infection after 4-5 weeks<sup>31</sup>. Induction of nitric oxide (NO)  
314 requires two canonical signals: IFN $\gamma$  and a microbial signal such as LPS<sup>35</sup>. Nitric oxide (NO)

315 production by NOS2-expressing macrophages can kill *M. tuberculosis in vitro* and has led to the  
316 paradigm that IFN $\gamma$  production by CD4 T cells induces NO production by macrophages, leading  
317 to control of *M. tuberculosis*<sup>36</sup>. The *in vivo* role of NO is less certain. NO regulates inflammation  
318 during *M. tuberculosis* infection *in vivo*<sup>33</sup>. We find NOS2 expression by macrophages was  
319 diminished only after CD4 depletion. NOS2 expression by macrophages was similar after CD4  
320 depletion or dual CD4 and CD8 depletion, indicating that CD8 T cells had no effect on NOS2  
321 expression and suggesting that CD8 T cells may not rely on the induction of NOS2 to control *M.*  
322 *tuberculosis*.

323 As CD4 depletion led to reduced NOS2 expression and increased frequency of YFP<sup>+</sup>  
324 macrophages, *in vivo* inhibition of NOS2 should mimic CD4 depletion should lead to a loss of  
325 bacterial control. Surprisingly, aminoguanidine treatment of *M. tuberculosis* infected mice had no  
326 effect on the intracellular *M. tuberculosis* burden within either AM or MDM, despite evidence of  
327 NO inhibition. However, we do observe increased recruitment of neutrophils as well as an  
328 increase in overall lung CFU, both of which have been previous reported following treatment with  
329 aminoguanidine<sup>33</sup>. One possibility is that the length of the treatment wasn't long enough to  
330 significantly perturb the intracellular burden to the point where we can detect intracellular  
331 changes. The lack of change on the intracellular *M. tuberculosis* burden following aminoguanidine  
332 treatment may also point towards an IFN $\gamma$ -independent effector mechanism for controlling the  
333 growth of intracellular *M. tuberculosis* within AM and MDM<sup>37, 38, 39</sup>.

334 The idea that AM ineffectively restricts *M. tuberculosis* is based on their "M2-like" nature  
335 and improved host control of pulmonary *M. tuberculosis* after their depletion<sup>40</sup>. David Russell's  
336 lab elegantly showed that IM (herein referred to as MDM) have a greater intrinsic ability to control  
337 *M. tuberculosis* than AM<sup>12</sup>. Thus, AM appear to be a sanctuary for *M. tuberculosis*. Yet, these  
338 data focus on early events after infection. Our data provide additional context for what  
339 subsequently happens. Early on, neutrophils, macrophages, and monocytes/DCs are infected  
340 similarly. However, once immune T cells are recruited to the lung, monocyte-derived

341 macrophages harbor the bulk of *M. tuberculosis* by five weeks after infection. A caveat of our  
342 studies is that they focus on relatively early (i.e., 3-5 wpi) interactions between T cells and lung  
343 macrophage subsets. Many studies show that early and late T cell responses differ greatly<sup>41</sup>. It  
344 will be important to characterize lung macrophage subsets and their interactions with T cells  
345 during chronic infection, although this remains technically challenging. Still, it is paradoxical that  
346 CD11c<sup>+</sup> MDM are better able to control *M. tuberculosis* infection<sup>12</sup> but are also the major niche  
347 for *M. tuberculosis*<sup>9</sup>. Our data shows that the relative permissiveness of macrophage for *M.*  
348 *tuberculosis* is modified by T cells. Initially, AM poorly constrain *M. tuberculosis*, but T cells  
349 dramatically improve the ability of AM to control intracellular infection. In the absence of T cells,  
350 AM emerge again as a haven for *M. tuberculosis*. In contrast, MDM become a niche where *M.*  
351 *tuberculosis* persists in the long term even in the presence of T cells.

352         Why would this be the case? We speculate that MDM are already optimally activated  
353 following *M. tuberculosis* infection and MDM have an intrinsic capacity to restrict *M. tuberculosis*.  
354 While T cells promote MDM control of *M. tuberculosis* infection, the magnitude of this effect is  
355 less than for AM. T cells, and T cell factors adds little to the intrinsic ability of MDM to control *M.*  
356 *tuberculosis* infection. Over time, their intrinsic activation could potentially impair their APC  
357 function if degradation of *M. tuberculosis* antigens prevented reduced their flow into antigen  
358 presentation pathways. Alternatively, we consider the possibility that macrophages with only one  
359 or two bacteria could be difficult for T cells to recognize. Interestingly, we observed that T cells  
360 reduced the bacillary content of infected cells to a point, and the minimum value was similar for  
361 all the different cell types. If the intrinsic antibacterial activity of MDM reduces the intracellular  
362 bacterial burden without killing the bacilli, the result could be a macrophage where *M. tuberculosis*  
363 persists but can't be recognized by T cells. Finally, there is an additional factor. Transfer of CD4  
364 T cells to RAG knockout mice leads to reduced CFU and YFP signal compared to un-transferred  
365 mice, showing CD4 T cells are critical to protection. However, CD4 T cells also promote the  
366 recruitment of macrophages to the lung, presumably through the elaboration of chemokines such



367 as CCL2, CCL5, or CX3CL1. Although monocyte and macrophage recruitment to an inflammatory  
368 site is generally viewed as a beneficial response, in the case of tuberculosis, it provides a new  
369 crop of macrophages that can be infected by *M. tuberculosis* and are permissive for its survival  
370 and replication.

371 **Methods**

372 **Ethics Statement.** Studies involving animals were conducted following relevant guidelines and  
373 regulations, and the studies were approved by the Institutional Animal Care and Use Committee  
374 at the University of Massachusetts Medical School (Animal Welfare A3306-01), using the  
375 recommendations from the Guide for the Care and Use of Laboratory Animals of the National  
376 Institutes of Health and the Office of Laboratory Animal Welfare.

377

378 **In vivo infection.** C57BL/6J were purchased from Jackson Laboratories (Bar Harbor, ME).  
379 H37Rv expressing yellow fluorescent protein (YFP) has been previously described<sup>9, 42</sup>. The mice  
380 were exposed to an aerosolized inoculum of Rv.YFP using a Glas-Col Inhalation Exposure  
381 System (Glas-Col LLC, Terre Haute, IN) as described<sup>34, 43</sup>. The number of *M. tuberculosis*  
382 deposited in the lungs was determined for each experiment and varied ranging between 37–90  
383 CFU.

384

385 **CD4 and CD8 T cell depletion.** 200 µg of either anti-CD4 (clone GK1.5) or anti-CD8 (clone 2.43)  
386 mAb were injected intra-peritoneally biweekly starting on day 21 for 14 days to deplete CD4 and/or  
387 CD8 T cells.

388

389 **Lung cell preparation.** To isolate total lung leukocytes, lungs were perfused by slowly injecting  
390 PBS into right ventricle immediately after mice were killed. The lungs were minced with a  
391 gentleMACS dissociator (Miltenyi) and digested (30 min, 37°C) in 250 U/ml collagenase and 60  
392 U/ml DNase (both from Sigma-Aldrich). Lung cell suspensions were passed through a 70-µm and  
393 40-µm strainers sequentially to remove cell clumps. Lung cells were resuspended in autoMACS  
394 running buffer (Miltenyi) that contains BSA, EDTA, and 0.09% sodium azide for subsequent  
395 staining.

396

397 **Flow cytometry analysis.** Cells were first stained with Zombie Fixable Viability dye (Biolegend)  
398 for 10 minutes at room temperature (RT), after which cells were stained with 5 ug/ml of anti-mouse  
399 CD16/32 mAb (BioXcell) in autoMACS running buffer (Miltenyi) for 10 minutes at 4°C. Next, the  
400 cells were then stained with a surface antibody cocktail for 20 minutes at 4°C. The antibodies  
401 included a dump channel was used to exclude T cells, B cells, and NK cells for efficient myeloid  
402 cell analysis and included anti-Thy1.2 (clone 30H12), anti-CD19 (clone 6D5), and anti-NK1.1  
403 (clone PK136) with PE-Cy7. Macrophages were subsequently defined based on a combination of  
404 CD11c (clone N418), SiglecF (clone E50-2440), Mertk (clone 2B10C42), CD64 (clone X54-5/7.1),  
405 Ly6c (clone HK1.4). To inactivate the bacteria, samples were fixed with 1%  
406 paraformaldehyde/PBS for 1 hour at room temperature and then washed with MACS buffer.  
407 Samples were run on either a 4 or 5 laser Cytex Aurora. Erdman (non-fluorescent) infected mice  
408 used for unstained control, single stains and YFP-FMO. Autofluorescence was treated as a  
409 fluorescent parameter during unmixing either automatically through the SpectralFlo software or  
410 by manually deriving an autofluorescence fingerprint (assigned to BV510). After unmixing FMOs  
411 were used to apply manual compensation to correct for unmixing anomalies. Flow data were  
412 analyzed using FlowJo v10.7.1.

413  
414 **Adoptive transfer model:** Spleens and lymph nodes from C57BL/6J mice were mechanically  
415 disrupted onto 70 µm strainers using the plungers of 3 mL syringes. CD4 T cells were purified  
416 from spleens and lymph nodes using MojoSort™ CD4 isolation kit and magnet (Biolegend).  
417 Purities of cells were determined for each experiment using flow cytometry. 2-5 million CD4 T  
418 cells were transferred into TCRα KO mice before infecting with Erdman.

419  
420 **Cell sorting.** Cells were sorted using Sony MA900 located in the biosafety level 3 lab in University  
421 of Massachusetts Medical School. Cells were stained with Zombie violet to exclude dead cells.  
422 Target cells were separated 2-way into polypropylene FACS tubes containing 2 ml of FBS. CD45

423 (clone 104) was used to identify hematopoietic cells, after which Thy1.2 (clone 30H12), CD19  
424 (clone 6D5) and Ly6G (clone 1A8) were used to remove lymphocytes and neutrophils.  
425 Macrophages were identified using a combination of CD11c (clone N418), SiglecF (clone E50-  
426 2440), Merck (clone 2B10C42), CD64 (clone X54-5/7.1).

427

428 ***Aminoguanidine treatment and NO quantification.*** Mice were supplied with drinking water  
429 containing 2.5% aminoguanidine hemisulfate (A7009-100G Sigma) starting from week 3 post  
430 infection. Water was replaced once a week. Nitric oxide levels were quantified in lung  
431 homogenates using a Greiss assay (G4410-10G Sigma) as previously described<sup>33</sup>.

432

433 ***Statistical analysis.*** Statistical analysis was performed using Prism 9 (GraphPad). P-values were  
434 calculated using unpaired t test, one-way ANOVA, or two-way ANOVA as indicated in the figure  
435 legends.

436

437 **Acknowledgements.** This work was funded by NIH/NIAID grants to S.M.B.: R01AI106725, R01  
438 AI123286, and P01 AI132130.

439

440 **Author contribution.** Conceptualization, R.L. and S.M.B.; Methodology, R.L., and J.L.;  
441 Investigation, R.L., T.W., T.R., and J.L.; Formal analysis, R.L., T.W., and S.M.B.; Writing &  
442 Editing, R.L., T.W., T.R., and J.L., and S.M.B.; Supervision, S.M.B.; Funding Acquisition, S.M.B.

443

444 **Declaration of interests.** The authors declare no competing interests.

445 **Figure legends.**

446

447 Figure 1: The effect of CD4 and CD8 T cell depletion on lung and spleen CFU.

448 (A) Experimental schematic. Mice were infected with Rv.YFP as indicated and rested for 3 weeks,  
449 after which CD4 and CD8 depleting mAbs were given over the course of two weeks at the  
450 indicated timepoints. (B) Proportion of CD4 and CD8 T cells in the lungs of infected C57BL/6 mice  
451 at 5 weeks post infection following treatment with either anti-CD4 and/or anti-CD8 depleting  
452 mAbs. (C) Lung and spleen CFU at 5 weeks post infection following treatment either anti-CD4  
453 and/or anti-CD8 depleting mAbs. Each point represents an individual mouse from two  
454 independent experiments (n=5/group) for week 3 data, and three independent experiments for  
455 week 5 data. Each condition was compared to the undepleted group using the Brown-Forsythe  
456 and Welch's ANOVA test was performed.

457

458 Figure 2: Distribution of *M. tuberculosis*-infected cells early after infection.

459 (A) Gating strategy for identifying various myeloid populations. In brief, a viability dye was used  
460 to exclude dead cells. CD3, CD19 and NK1.1 were used to exclude lymphocytes and NK cells  
461 from the hematopoietic cells. Mertk and CD64 were used to separate macrophages from  
462 monocyte/DC subsets. SiglecF and CD11c were used to separate AM from MDM populations,  
463 then used to subset various MDM populations. CD11b was used to subset different AM  
464 populations. CD11c and Ly6c were used to subset various monocyte/DC populations. (B)  
465 Quantification of various myeloid cells in the lung at week 3 and week 5 post infection, expressed  
466 in terms of total cell numbers (top) or as a percentage of total myeloid cells (bottom). (C)  
467 Quantification of the YFP signal in various myeloid cells in the lung at week 3 and week 5 post  
468 infection, expressed in terms of total cell numbers (top), %YFP of each population (middle) or the  
469 fraction of each population of the total YFP+ cells (bottom). (D) Flow sorted AM and MDM2 were  
470 plated to determine intracellular CFU within each purified population. (C, D) Each point represents

471 an individual mouse from two independent experiment (n=5/group) for week 3 data, and three  
472 independent experiments for week 5 data. A two-way ANOVA was performed using Bonferonni's  
473 multiple comparison test. (D) Representative results from two different experiments using cells  
474 purified from lung cells pooled from five mice, tested in triplicate, and analyzed using a t-test.

475

476 Figure 3: Lung myeloid cells react differently to the loss of CD4 and CD8 T cell pressures.  
477 Quantification of YFP signal within various myeloid populations in the lung at 5 weeks post  
478 infection following CD4 and/or CD8 depletion. (A) Representative flow plots of YFP signal in AM1  
479 and MDM2, plotted against autofluorescence. Top number represents the frequency of YFP+  
480 events, bottom number are the total number of YFP+ cells. (B-D) Graphical representation of YFP  
481 signal in different myeloid subsets, expressed as (B) %YFP+ cells within each subset (C) MFI of  
482 YFP within each subset (D) and %YFP+ cells out of total myeloid cells. Each point represents an  
483 individual mouse from two independent experiments (n=5/group). A two-way ANOVA was  
484 performed using Tukey's multiple comparison test. Some statistical comparisons have been  
485 omitted for clarity.

486

487 Figure 4: T cell depletion affects NOS2 expression. (A) The percentage of different myeloid cell  
488 types in the lung that express NOS2 5 wpi. (B) Correlation between %NOS2 expression and  
489 %YFP signal in various myeloid populations. (C) The percentage of infected (YFP+) cells that  
490 express NOS2. (D) The effect of CD4 and/or CD8 T cell depletion on the distribution of YFP+ cells  
491 among NOS2+ and NOS2- cells, as a percentage of total myeloid cells in the lung 5 wpi. (E) Data  
492 from panel D expressed as a ratio of NOS2+ vs. NOS2- cells. Each point represents an individual  
493 mouse. The data is representative data from one of two independent experiments (n=5/group). A  
494 two-way ANOVA was performed using Šídák's multiple comparisons test.

495

496 Figure 5: Inhibition of NOS2 does not increase intracellular bacterial burden. (A) Experimental  
497 schematic for AG treatment. Mice were giving AG in their drinking water starting from week 3 post  
498 infection over the course of two weeks. (B) Lung and spleen CFU from mice treated with AG at 5  
499 wpi. (C) Total numbers of various myeloid populations in the lung at 5 wpi. (D) %YFP+ as a  
500 fraction of total myeloid cells following AG treatment at 5 wpi. Each point represents an individual  
501 mouse from two independent experiments (n=5/group). A two-way ANOVA was performed using  
502 Tukey's multiple comparison test (D) or Dunnett's test (E).

503

504 Figure 6. Adoptive transfer of CD4 T cells drive recruitment of MDM to the lung. (A) Experimental  
505 schematic for CD4 T cell adoptive transfer. RAG<sup>-/-</sup> were infected with Rv.YFP as indicated and  
506 rested for 3 weeks. In parallel, C57BL/6 mice were also infected with *M. tuberculosis* Erdman  
507 strain, and at 3 wpi, polyclonal CD4 T cells were purified and transferred i.v. into the RAG<sup>-/-</sup> mice.  
508 Cells were isolated from RAG<sup>-/-</sup> mice two weeks post transfer, and bacterial burden was also  
509 examined. (B) Lung CFU was determined in RAG<sup>-/-</sup> mice that either received CD4 T cells or PBS.  
510 (C) Total numbers of various myeloid populations were also enumerated at this timepoint. (D) %  
511 YFP (left) and the MFI of YFP (right) within each myeloid population was examined. (E) Total  
512 number of YFP+ cells within each myeloid subset (left) and the % of infected cells within each  
513 population as a fraction of total infected cells (right). The data is representative data from one of  
514 three independent experiments (n=5/group). Statistical analysis was performed using a t-test (B),  
515 a two-way ANOVA with Tukey's multiple comparison test (C), or Šídák's multiple comparisons (D,  
516 E).

517

518



519  
520  
521  
522  
523  
  
524  
525  
526  
527  
  
528  
529  
530  
531  
  
532  
533  
534  
  
535  
536  
537  
  
538  
539  
540  
  
541  
542  
543  
  
544  
545  
546  
  
547  
548  
549  
550  
  
551  
552  
553  
  
554  
555  
556

## References

1. Cohen SB, *et al.* Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination. *Cell Host Microbe* **24**, 439-446 e434 (2018).
2. Wolf AJ, *et al.* Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. *J Exp Med* **205**, 105-115 (2008).
3. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis Is Influenced by Host Factors and Precedes the Initiation of T-Cell Immunity. *Infection and Immunity* **70**, 4501-4509 (2002).
4. Skold M, Behar SM. Tuberculosis triggers a tissue-dependent program of differentiation and acquisition of effector functions by circulating monocytes. *J Immunol* **181**, 6349-6360 (2008).
5. Norris BA, Ernst JD. Mononuclear cell dynamics in M. tuberculosis infection provide opportunities for therapeutic intervention. *PLoS Pathog* **14**, e1007154 (2018).
6. Gonzalez-Juarrero M, Shim TS, Kipnis A, Junqueira-Kipnis AP, Orme IM. Dynamics of macrophage cell populations during murine pulmonary tuberculosis. *J Immunol* **171**, 3128-3135 (2003).
7. Wolf AJ, *et al.* Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. *J Immunol* **179**, 2509-2519 (2007).
8. Repasy T, *et al.* Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis in vivo. *PLoS Pathog* **9**, e1003190 (2013).
9. Lee J, Boyce S, Powers J, Baer C, Sasseti CM, Behar SM. CD11c<sup>hi</sup> monocyte-derived macrophages are a major cellular compartment infected by Mycobacterium tuberculosis. *PLoS Pathog* **16**, e1008621 (2020).
10. Bryson BD, *et al.* Heterogeneous GM-CSF signaling in macrophages is associated with control of Mycobacterium tuberculosis. *Nat Commun* **10**, 2329 (2019).
11. Pisu D, Huang L, Grenier JK, Russell DG. Dual RNA-Seq of Mtb-Infected Macrophages In Vivo Reveals Ontologically Distinct Host-Pathogen Interactions. *Cell Rep* **30**, 335-350 e334 (2020).

- 557 12. Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. Growth of *Mycobacterium tuberculosis* in vivo  
558 segregates with host macrophage metabolism and ontogeny. *J Exp Med*, (2018).  
559
- 560 13. Rothchild AC, *et al.* Alveolar macrophages generate a noncanonical NRF2-driven transcriptional  
561 response to *Mycobacterium tuberculosis* in vivo. *Sci Immunol* **4**, (2019).  
562
- 563 14. Pisu D, *et al.* Single cell analysis of *M. tuberculosis* phenotype and macrophage lineages in the  
564 infected lung. *J Exp Med* **218**, (2021).  
565
- 566 15. Srivastava S, Ernst JD. Cutting edge: Direct recognition of infected cells by CD4 T cells is required  
567 for control of intracellular *Mycobacterium tuberculosis* in vivo. *J Immunol* **191**, 1016-1020  
568 (2013).  
569
- 570 16. Yang JD, *et al.* *Mycobacterium tuberculosis*-specific CD4+ and CD8+ T cells differ in their capacity  
571 to recognize infected macrophages. *PLoS Pathog* **14**, e1007060 (2018).  
572
- 573 17. Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-specific CD4+ effector  
574 cells enables persistence of *M. tuberculosis* in vivo. *PLoS Pathog* **7**, e1002063 (2011).  
575
- 576 18. Patankar YR, *et al.* Limited recognition of *Mycobacterium tuberculosis*-infected macrophages by  
577 polyclonal CD4 and CD8 T cells from the lungs of infected mice. *Mucosal Immunol* **13**, 140-148  
578 (2020).  
579
- 580 19. Sutiwisesak R, *et al.* A natural polymorphism of *Mycobacterium tuberculosis* in the *esxH* gene  
581 disrupts immunodomination by the TB10.4-specific CD8 T cell response. *PLOS Pathogens* **16**,  
582 e1009000 (2020).  
583
- 584 20. Lewinsohn DA, Heinzl AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. *Mycobacterium*  
585 *tuberculosis*-specific CD8+ T cells preferentially recognize heavily infected cells. *Am J Respir Crit*  
586 *Care Med* **168**, 1346-1352 (2003).  
587
- 588 21. Mott D, Yang J, Baer C, Papavinasasundaram K, Sasseti CM, Behar SM. High Bacillary Burden  
589 and the ESX-1 Type VII Secretion System Promote MHC Class I Presentation by *Mycobacterium*  
590 *tuberculosis*-Infected Macrophages to CD8 T Cells. *J Immunol* **210**, 1531-1542 (2023).  
591
- 592 22. McCubbrey AL, Allison KC, Lee-Sherick AB, Jakubzick CV, Janssen WJ. Promoter Specificity and  
593 Efficacy in Conditional and Inducible Transgenic Targeting of Lung Macrophages. *Front Immunol*  
594 **8**, 1618 (2017).  
595

- 596 23. Aegerter H, *et al.* Influenza-induced monocyte-derived alveolar macrophages confer prolonged  
597 antibacterial protection. *Nat Immunol* **21**, 145-157 (2020).  
598
- 599 24. Misharin AV, *et al.* Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the  
600 lung over the life span. *J Exp Med* **214**, 2387-2404 (2017).  
601
- 602 25. Ural BB, *et al.* Identification of a nerve-associated, lung-resident interstitial macrophage subset  
603 with distinct localization and immunoregulatory properties. *Sci Immunol* **5**, (2020).  
604
- 605 26. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium  
606 tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. *Infect*  
607 *Immun* **70**, 4501-4509 (2002).  
608
- 609 27. Cooper AM. Cell-Mediated Immune Responses in Tuberculosis. *Annual Review of Immunology*  
610 **27**, 393-422 (2009).  
611
- 612 28. Lewinsohn DM, Lewinsohn DA. The Missing Link in Correlates of Protective Tuberculosis  
613 Immunity: Recognizing the Infected Cell. *Front Immunol* **13**, 869057 (2022).  
614
- 615 29. Jamaati H, *et al.* Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis. *Front Microbiol*  
616 **8**, 2008 (2017).  
617
- 618 30. Mogue T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets  
619 in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice.  
620 *The Journal of experimental medicine* **193**, 271-280 (2001).  
621
- 622 31. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric  
623 oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci U S A* **94**, 5243-5248  
624 (1997).  
625
- 626 32. Mishra BB, *et al.* Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3  
627 inflammasome-dependent processing of IL-1beta. *Nat Immunol* **14**, 52-60 (2013).  
628
- 629 33. Mishra BB, *et al.* Nitric oxide prevents a pathogen-permissive granulocytic inflammation during  
630 tuberculosis. *Nat Microbiol* **2**, 17072 (2017).  
631

- 632 34. Lu YJ, Barreira-Silva P, Boyce S, Powers J, Cavallo K, Behar SM. CD4 T cell help prevents CD8 T cell  
633 exhaustion and promotes control of Mycobacterium tuberculosis infection. *Cell Rep* **36**, 109696  
634 (2021).  
635
- 636 35. Lowenstein CJ, *et al.* Macrophage nitric oxide synthase gene: two upstream regions mediate  
637 induction by interferon gamma and lipopolysaccharide. *Proc Natl Acad Sci U S A* **90**, 9730-9734  
638 (1993).  
639
- 640 36. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of a  
641 new paradigm for protective immunity to TB. *Nat Rev Microbiol* **12**, 289-299 (2014).  
642
- 643 37. Lu LL, *et al.* IFN- $\gamma$ -independent immune markers of Mycobacterium tuberculosis exposure.  
644 *Nature Medicine* **25**, 977-987 (2019).  
645
- 646 38. Van Dis E, *et al.* IFN-gamma-independent control of M. tuberculosis requires CD4 T cell-derived  
647 GM-CSF and activation of HIF-1 $\alpha$ . *PLoS Pathog* **18**, e1010721 (2022).  
648
- 649 39. Sakai S, *et al.* CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary  
650 Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal  
651 Disease. *PLoS Pathog* **12**, e1005667 (2016).  
652
- 653 40. Khan A, Singh VK, Hunter RL, Jagannath C. Macrophage heterogeneity and plasticity in  
654 tuberculosis. *J Leukoc Biol* **106**, 275-282 (2019).  
655
- 656 41. Jayaraman P, *et al.* TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis  
657 Infection. *PLoS Pathog* **12**, e1005490 (2016).  
658
- 659 42. Lovewell RR, Baer CE, Mishra BB, Smith CM, Sasseti CM. Granulocytes act as a niche for  
660 Mycobacterium tuberculosis growth. *Mucosal Immunol*, (2020).  
661
- 662 43. Lai R, *et al.* Host genetic background is a barrier to broadly effective vaccine protection:  
663 Relevance to BCG and Mycobacterium tuberculosis Infection. *J Clin Invest* (**in press**), (2023).  
664  
665




Figure 1






Figure 2







Figure 3




Figure 4






Figure 5




Figure 6




Figure S1

